Skip to main content

Table 1 Baseline characteristics of the participants by serum AOPP categories

From: Association between serum advanced oxidation protein products and mortality risk in maintenance hemodialysis patients

Variables Baseline serum AOPP, µmol/L P-value
 < 87  ≥ 87
N 1126 441  
Male, no. (%) 649 (57.6) 247 (56.0) 0.558
Age, year 55.0 ± 15.6 58.4 ± 14.2  < 0.001
Dialysis vintage, month 28.9 (11.8–60.5) 35.1 (18.6–67.9)  < 0.001
BMI, kg/m2 21.3 ± 3.3 22.2 ± 3.7  < 0.001
MAP, mmHg 103.1 ± 14.0 101.6 ± 14.3 0.055
Smoking, no. (%) 134 (11.9) 66 (15.0) 0.102
CVD, no. (%) 562 (49.9) 241 (54.6) 0.092
Diabetes, no. (%) 557 (49.5) 262 (59.4)  < 0.001
Hypertension, no. (%) 1028 (91.3) 410 (93.0) 0.278
Laboratory results    
 C-reactive protein, mg/L 3.4 (1.8–10.3) 4.7 (2.9–10.3) 0.011
 Albumin, g/L 39.7 ± 6.3 39.6 ± 6.8 0.886
 Hemoglobin, g/L 102.4 ± 20.5 105.4 ± 18.7 0.008
 White blood cells, 109/L 5.9 ± 1.9 6.2 ± 2.0 0.009
 Calcium, mmol/L 2.2 ± 0.3 2.3 ± 0.3 0.055
 Phosphate, mmol/L 1.9 ± 0.7 2.1 ± 0.7  < 0.001
 iPTH, pg/mL 258 (131.2–500.3) 280.7 (138.5–608.9) 0.147
 Total cholesterol, mmol/L 4.0 ± 1.0 4.4 ± 1.2  < 0.001
 TG, mmol/L 1.1 (0.8–1.6) 1.8 (1.1–2.7)  < 0.001
 AOPP, μmol/L 68 ± 11 105 ± 19  < 0.001
Medication use, no. (%)    
 ACEI/ARB 564 (50.1) 214 (48.5) 0.578
 Glucose-lowering drugs 135 (12.0) 85 (19.3)  < 0.001
 Lipid-lowering drugs 98 (8.7) 42 (9.5) 0.609
 Antiplatelet drugs 146 (13.0) 51 (11.6) 0.452
 Iron supplement 598 (53.1) 219 (49.7) 0.219
 Phosphorus binder 439 (39.0) 205 (46.5) 0.007
  1. Continuous variables are presented as Mean ± SDs or median (interquartile range), categorical variables are presented as no. (%)
  2. BMI body mass index, MAP mean arterial pressure, CVD cardiovascular disease, iPTH parathyroid hormone, TG triglyceride, AOPP advanced oxidation protein products